ROR1 and lung carcinoma: Srivastava et al. have shown that oxaliplatin, known as a strong ICD inducer, could improve the efficacy of receptor tyrosine kinase-like orphan receptor 1 (ROR1)-specific CAR-T therapy in combination with ICIs in breast and lung cancer in mice model [37].